Inactive Instrument

US Rare Earth Minerals Inc Stock Other OTC

US9034101082

Biotechnology & Medical Research

End-of-day quote Other OTC Other stock markets
- ^USD	-

08-04	Bioxytran, Inc. and University Of Minnesota Department Of Chemistry Execute Second Sponsored Research Agreement To Advance ASI-Powered Carbohydrate Drug Design Platform	CI
07-30	US officials pressed China on rare earths, farm goods commitments, Bessent says	RE

Valuation: US Rare Earth Minerals Inc

Market Cap	2.52M 2.19M 2.04M 1.87M 3.54M 240M 3.58M 23.94M 9.4M 120M 9.48M 9.27M 398M	P/E 2024	-5.27x	P/E 2025	-3.28x
Enterprise Value	3.26M 2.83M 2.64M 2.42M 4.58M 310M 4.63M 30.97M 12.15M 155M 12.26M 11.99M 514M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99.38%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : US Rare Earth Minerals Inc

08-04	Bioxytran, Inc. and University Of Minnesota Department Of Chemistry Execute Second Sponsored Research Agreement To Advance ASI-Powered Carbohydrate Drug Design Platform	CI
07-30	US officials pressed China on rare earths, farm goods commitments, Bessent says	RE
07-29	Bioxytran Announces Publication of Corporate Research Report Discussing Prolectin-M Phase 2 Results, Planned 408-Patient Registrational Trial, Bxt-25 Oxygen-Therapeutic Platform, and A-Suqar Commercial Distribution Agreement	CI
07-16	Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst	RE
05-15	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-15	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Bioxytran, Inc. Auditor Raises 'Going Concern' Doubt	CI
03-17	Bioxytran, Inc. announced that it has received $1.158942 million in funding	CI
03-04	Bioxytran Inc Announces Positive Dose Optimization Results And Advances Toward Phase 3 Registrational Trial For ProLectin-M	CI
03-02	Bioxytran Inc reports positive phase 1b/2a clinical study results for Prolectin-M, broad-range antiviral drug in mild to moderate Covid-19	RE
02-17	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical Ltd for A-SUQAR Dietary Supplement	CI
02-11	Bioxytran reports positive phase 2 results demonstrating rapid viral clearance with Prolectin-Mbioxytran	RE
02-11	Bioxytran, Inc. Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with Prolectin-Mbioxytran	CI

More news

Press Releases: US Rare Earth Minerals Inc

08-04	Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs	AQ
07-29	Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research	AQ
05-29	Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25	AQ
03-20	BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT	AQ
03-04	Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M	AQ

More press releases

Managers and Directors: US Rare Earth Minerals Inc

Manager	Title	Age	Since
David Platt CEO	Chief Executive Officer	73	2018-08-31
Ola Soderquist DFI	Director of Finance/CFO	65	2018-08-31
Leslie Ajayi CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Dale Conaway BRD	Director/Board Member	71	2018-11-01
Alan Hoberman BRD	Director/Board Member	73	2018-11-01
David Platt CHM	Chairman	73	2018-08-31

More insiders

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Employees

Sector

Biotechnology & Medical Research

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.35%	+16.60%	+58.11%	+95.21%	64.9B
ARGENX SE	+1.84%	+2.04%	+30.76%	+72.31%	54.05B
BIONTECH SE	+0.91%	-0.83%	-17.01%	-13.43%	23.16B
INSMED INCORPORATED	+0.27%	-3.98%	-11.28%	+350.30%	21.46B
WUXI BIOLOGICS (CAYMAN) INC.	+1.87%	+9.47%	+30.87%	-5.63%	21.25B
GENMAB A/S	+0.69%	+3.36%	+38.42%	-24.99%	17.94B
PHARMAESSENTIA CORPORATION	+9.88%	+23.61%	+222.87%	+385.49%	17.03B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.29%	+5.61%	+21.01%	+636.23%	14.99B
EXELIXIS, INC.	+1.25%	+2.48%	+51.36%	+179.72%	14.25B
Average	+2.70%	+5.03%	+47.23%	+186.13%	27.67B
Weighted average by Cap.	+2.78%	+5.90%	+44.11%	+142.10%

	2024	2025
Net sales	-	-
Net income	-2.37M -2.05M -1.91M -1.76M -3.32M -225M -3.35M -22.45M -8.81M -113M -8.89M -8.69M -373M	-2.12M -1.84M -1.71M -1.58M -2.98M -202M -3.01M -20.14M -7.91M -101M -7.97M -7.8M -335M
Net Debt	1.09M 943K 879K 809K 1.53M 104M 1.54M 10.33M 4.05M 51.81M 4.09M 4M 172M	741K 642K 598K 550K 1.04M 70.44M 1.05M 7.03M 2.76M 35.24M 2.78M 2.72M 117M

US Rare Earth Minerals Inc Stock Other OTC

Stocks

US9034101082

Biotechnology & Medical Research

Valuation: US Rare Earth Minerals Inc

Latest news : US Rare Earth Minerals Inc

Press Releases: US Rare Earth Minerals Inc

Managers and Directors: US Rare Earth Minerals Inc

Bio Therapeutic Drugs

Financials

Company Profile